Supriya Lifescience Ltd announced the earnings call transcript for Q3 FY 2024-25, discussing their current and future revenue expectations, including new product launches and contract manufacturing opportunities. The company anticipates revenue to significantly grow from a new whey protein product expected in FY '26 after receiving their FSSAI license.